Syndax Posts Impressive Financial Results for Q3 2025

November 4, 2025 - 04:24

Syndax has reported robust financial results for the third quarter of 2025, showcasing significant growth and strong market demand for its products. The company achieved total revenue of $45.9 million, marking a 21% increase compared to the previous quarter. This growth was primarily driven by Revuforj® (revumenib), which generated net revenue of $32.0 million. Notably, prescriptions for Revuforj surged by 25% over the second quarter, indicating a rising interest and demand for the treatment.

Additionally, Niktimvo™ (axatilimab-csfr) contributed $45.8 million in net revenue, reported by Incyte, alongside $13.9 million in collaboration revenue for Syndax. A significant milestone was reached on October 24, 2025, when Revuforj received FDA approval for the treatment of relapsed/refractory NPM1m acute myeloid leukemia, further enhancing its market position.

With a strong financial foundation, Syndax holds $456.1 million in cash, cash equivalents, and investments, positioning the company well for future growth and development.